After Hours
$
0.56
Change
+0.0061 +1.11%
Volume
Volume 298
Feb 2, 2023, 7:42 p.m.
Quotes are delayed by 20 min
Today's close
$ 0.52
$ 0.55
Change
+0.03 +5.46%
Day low
Day high
$0.52
$0.56

52 week low
52 week high
$0.36
$1.89

Market cap
$46.07M
Average volume
122,439
P/E ratio
11.80
Rev. per Employee
$1.28M
EPS
0.05
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on LPCN
-
Lipocine stock price target cut to $2.50 from $4.00 at Ladenburg Thalmann
- Tomi Kilgore
-
Lipocine shares plummet 35% after FDA fails to approve its testosterone replacement therapy
- Emma Court
-
Lipocine downgraded to hold from buy at Canaccord
- Tomi Kilgore
-
Lipocine stock price target cut to $2 from $11 at Canaccord
- Tomi Kilgore
-
Bed Bath & Beyond surges on earnings
- MarketWatch
Analyst Ratings
Other News on LPCN
-
- Edgar Online - (EDG = 10Q, 10K)
-
- Edgar Online - (EDG = 10Q, 10K)
-
MVIS, MRIN and CLVR among mid-day movers
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
BGVF, VYNT and SNMP among pre market gainers
- Seeking Alpha
-
Warning: LPCN is at high risk of performing badly
- Seeking Alpha
-
AG, FRO and WATT among pre market gainers
- Seeking Alpha
-
FDA affirms class 1 NDA resubmission for Lipocine's Tlando
- Seeking Alpha
-
Lipocine discloses mid-stage data for NASH candidate
- Seeking Alpha
- Loading more headlines...
Press Releases on LPCN
-
Lipocine to Present at Biotech Showcase
- PR Newswire - PRF
-
Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference
- PR Newswire - PRF
-
Lipocine to Participate in the Cantor Neurology & Psychiatric Conference
- PR Newswire - PRF
-
Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference
- PR Newswire - PRF
-
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022
- PR Newswire - PRF
-
FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment
- PR Newswire - PRF
-
LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS
- PR Newswire - PRF
-
LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE
- PR Newswire - PRF
-
Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
- PR Newswire - PRF
-
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
- PR Newswire - PRF
-
Lipocine Announces Financial Results for the Year Ended December 31, 2021
- PR Newswire - PRF
-
Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH
- PR Newswire - PRF
-
NetworkNewsBreaks - Lipocine, Inc. (NASDAQ: LPCN) Closes $6M Follow-On
- NetworkNewsWire
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com